

Roberto Castelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9084999/publications.pdf>

Version: 2024-02-01

77
papers

1,835
citations

331538

21
h-index

276775

41
g-index

77
all docs

77
docs citations

77
times ranked

2130
citing authors

#	ARTICLE	IF	CITATIONS
1	Rheumatoid Factors: Clinical Applications. <i>Disease Markers</i> , 2013, 35, 727-734.	0.6	211
2	Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: Comparison of treated and untreated patients. <i>Journal of Allergy and Clinical Immunology</i> , 1997, 99, 194-196.	1.5	148
3	Heparin Induced Thrombocytopenia: Pathogenetic, Clinical, Diagnostic and Therapeutic Aspects. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2007, 7, 153-162.	0.2	127
4	Acquired Deficiency of the Inhibitor of the First Complement Component: Presentation, Diagnosis, Course, and Conventional Management. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 669-690.	0.7	101
5	Angioedema due to acquired C1-inhibitor deficiency: A bridging condition between autoimmunity and lymphoproliferation. <i>Autoimmunity Reviews</i> , 2008, 8, 156-159.	2.5	96
6	Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. <i>Blood Advances</i> , 2019, 3, 1197-1210.	2.5	76
7	Lymphoproliferative disease and acquired C1 inhibitor deficiency. <i>Haematologica</i> , 2007, 92, 716-718.	1.7	73
8	Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 1336-1351.	0.8	73
9	The heparins and cancer: review of clinical trials and biological properties. <i>Vascular Medicine</i> , 2004, 9, 205-213.	0.8	69
10	Syncope in patients with pulmonary embolism: comparison between patients with syncope as the presenting symptom of pulmonary embolism and patients with pulmonary embolism without syncope. <i>Vascular Medicine</i> , 2003, 8, 257-261.	0.8	68
11	Acquired C1-inhibitor deficiency and lymphoproliferative disorders: A tight relationship. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 323-332.	2.0	59
12	Thrombosis and Hemostatic Abnormalities in Hematological Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 441-450.	0.2	47
13	Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. <i>Transfusion</i> , 1995, 35, 209-212.	0.8	45
14	High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibitor deficiency. <i>British Journal of Haematology</i> , 2016, 172, 902-908.	1.2	41
15	Thromboembolic Complications in Malignant Haematological Disorders. <i>Current Vascular Pharmacology</i> , 2010, 8, 482-494.	0.8	36
16	The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 207-14.	1.4	36
17	Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review. <i>International Journal of Laboratory Hematology</i> , 2008, 30, 425-431.	0.7	34
18	Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. <i>Annals of Hematology</i> , 2014, 93, 1523-1529.	0.8	27

#	ARTICLE	IF	CITATIONS
19	Intrathoracic Masses Due to Extramedullary Hematopoiesis. American Journal of the Medical Sciences, 2004, 328, 299-303.	0.4	26
20	Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 1-7.	0.2	26
21	Interaction of C1 inhibitor with thrombin on the endothelial surface. Blood Coagulation and Fibrinolysis, 2011, 22, 571-575.	0.5	22
22	The Impact of an Aging Population on the Diagnosis of Pulmonary Embolism: Comparison of Young and Elderly Patients. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 65-72.	0.7	21
23	Current and Emerging Treatment Options for Patients with Relapsed Myeloma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S8014.	0.6	21
24	Inflammatory and prothrombotic parameters in normotensive non-diabetic obese women: effect of weight loss obtained by gastric banding. Internal and Emergency Medicine, 2012, 7, 237-242.	1.0	19
25	Pulmonary embolism in elderly patients: Prognostic impact of the Cumulative Illness Rating Scale (CIRS) on short-term mortality. Thrombosis Research, 2014, 134, 326-330.	0.8	19
26	High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy. Digestive and Liver Disease, 2016, 48, 1394-1397.	0.4	19
27	Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization. Medical Oncology, 2018, 35, 118.	1.2	18
28	Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leukemia Research, 2015, 39, 525-529.	0.4	17
29	Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course. Clinical and Experimental Immunology, 2020, 201, 258-265.	1.1	17
30	Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor. Transfusion, 1998, 38, 307-311.	0.8	16
31	Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacology and Immunotoxicology, 2012, 34, 740-753.	1.1	16
32	High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. Journal of Thrombosis and Thrombolysis, 2018, 45, 106-113.	1.0	14
33	Abnormal Hemostatic Parameters and Risk of Thromboembolism Among Patients With COVID-19 Infection. Journal of Hematology (Brossard, Quebec), 2020, 9, 1-4.	0.4	14
34	Laboratory and clinical risk assessment to treat myelodysplastic syndromes. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1411-1426.	1.4	12
35	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer Journal, 2021, 11, 167.	2.8	11
36	The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes. Medical Oncology, 2018, 35, 33.	1.2	10

#	ARTICLE	IF	CITATIONS
37	First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas. <i>Medical Oncology</i> , 2018, 35, 15.	1.2	10
38	HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2020, 20, 175-180.	0.2	10
39	Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents. <i>Medical Oncology</i> , 2018, 35, 76.	1.2	9
40	Mutational profile of ZBTB16 ^{hi} CD34 ⁺ positive acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 3839-3847.	1.3	9
41	Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. <i>Anti-Cancer Drugs</i> , 2015, 26, 1078-1082.	0.7	8
42	Successful management with intravenous immunoglobulins in alemtuzumab-induced acute inflammatory demyelinating neuropathy: clinical report of three patients. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 717-720.	1.1	7
43	Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 22-32.	1.4	7
44	Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study. <i>Annals of Hematology</i> , 2017, 96, 779-786.	0.8	7
45	Prothrombotic and Inflammatory Markers in Elderly Patients with Non-Alcoholic Hepatic Liver Disease before and after Weight Loss: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4906.	1.0	7
46	Cardiopulmonary By-pass in a Patient with Acquired C1 Inhibitor Deficiency. <i>International Journal of Artificial Organs</i> , 1997, 20, 175-177.	0.7	6
47	The Value of Four-Detector Row Spiral Computed Tomography for the Diagnosis of Pulmonary Embolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 831-837.	1.5	6
48	BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016030.	0.5	6
49	Therapeutic options for patients with angioedema due to C1-inhibitor deficiencies: from pathophysiology to the clinic. <i>Immunopharmacology and Immunotoxicology</i> , 2013, 35, 181-190.	1.1	5
50	Choosing treatment options for patients with relapsed/refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 199-215.	1.1	5
51	Neutrophilic progression in a case of polycythemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. <i>Pathology Research and Practice</i> , 2015, 211, 341-343.	1.0	5
52	Personalized treatment strategies for elderly patients with myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2017, 10, 1077-1086.	1.0	5
53	Risk Of Thrombosis In Elderly Immune Primary Trombocytopenic Patients Treated with Thrombopoietin Receptors Agonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 903-907.	1.0	5
54	Unreliable estimation of HbA1c due to the presence of Camperdown haemoglobin [beta 104 (G6) Arg Ser]. <i>Diabetic Medicine</i> , 2004, 21, 377-379.	1.2	4

#	ARTICLE	IF	CITATIONS
55	Aggressive natural killer cell leukaemia with a complex karyotype: a case report. <i>Annals of Hematology</i> , 2006, 85, 66-68.	0.8	4
56	Unusual severe development of common B lymphoblastic leukemia in Gaucher disease type I. <i>American Journal of Hematology</i> , 2006, 81, 383-384.	2.0	3
57	Ibrutinib related bleeding complications in elderly patients with B cell malignancies. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 694-696.	1.0	3
58	Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 155-156.	1.0	3
59	Massive Right Atrial Thrombosis: Are You Brave Enough to Start Anticoagulation? A Case Report. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 688351.	1.1	3
60	Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release. <i>Journal of Clinical Medicine</i> , 2022, 11, 2720.	1.0	3
61	Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA. <i>European Journal of Internal Medicine</i> , 2010, 21, 25-29.	1.0	2
62	Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e461-e467.	0.2	2
63	HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2020, 20, 175-180.	0.2	2
64	New antithrombotic agents. <i>Panminerva Medica</i> , 2006, 48, 247-56.	0.2	2
65	Lymphoproliferative disease and Acquired C1 inhibitor (C1-INH) deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, S279.	1.5	1
66	Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatments. <i>Anti-Cancer Drugs</i> , 2021, 32, 323-329.	0.7	1
67	PULMONARY EMBOLISM IN ELDERLY. <i>European Journal of Internal Medicine</i> , 2008, 19, S40.	1.0	0
68	P-312 Recombinant human erythropoietin improves quality of life and brain function in elderly patients with low-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2013, 37, S163.	0.4	0
69	An Unusual Hypereosinophilic Syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB169.	1.5	0
70	Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant. <i>Annals of Hematology</i> , 2018, 97, 2523-2525.	0.8	0
71	Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 163-166.	0.5	0
72	Risk-tailored treatment of splenic marginal zone lymphoma. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	0

#	ARTICLE	IF	CITATIONS
73	Lymphoproliferative Disorder and Acquired C1-INH Deficiency. A Case Series of 48 Patients. Blood, 2011, 118, 1596-1596.	0.6	0
74	Salvage Therapy with Bortezomib and Dexamethasone in Elderly Patients with Relapsed Refractory Multiple Myeloma. Blood, 2015, 126, 5378-5378.	0.6	0
75	High Prevalence of Marginal ZONE Lymphoma Among Patients with Acquired C1- Inhibitor Deficiency. Blood, 2015, 126, 1444-1444.	0.6	0
76	Myelodysplastic syndromes and elderly patients.. , 2018, 01, .		0
77	Cardiopulmonary by-pass in a patient with acquired C1 inhibitor deficiency. International Journal of Artificial Organs, 1997, 20, 175-7.	0.7	0